Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Single-center Study of CM313 in Patients With Pemphigus
Sponsor: Sichuan Provincial People's Hospital
Summary
A prospective, single-center, single-arm clinical study aimed to explore the efficacy and safety of the anti-CD38 monoclonal antibody CM313 combined with low-dose glucocorticoids in patients with pemphigus.
Official title: A Prospective, Single-Center, Single-Arm Clinical Study to Evaluate the Novel Humanized Cluster of Differentiation 38(CD38) Monoclonal Antibody (CM313) for the Treatment of Pemphigus
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2025-04-01
Completion Date
2028-04-01
Last Updated
2025-04-01
Healthy Volunteers
No
Conditions
Interventions
CM313 injection
600 mg (4 mL per vial), administer once at Week 0, 1, and 2, and then every 6 months thereafter or determined based on clinical assessment
glucocorticoids
Administer medium- or long-acting glucocorticoids 1-3 hours before injection
Locations (1)
Sichuan Provincial People's Hospital
Chengdu, China